ETNB Jan 2025 22.500 put
| Previous close | 10.00 |
| Open | 10.00 |
| Bid | 13.70 |
| Ask | 15.50 |
| Strike | 22.50 |
| Expiry date | 2025-01-17 |
| Day's range | 8.08 - 10.00 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
GlobeNewswire89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
—With the initiation of ENLIGHTEN-Cirrhosis, pegozafermin is the first FGF21 analog to enter a Phase 3 trial in MASH patients with compensated cirrhosis (F4)— —Regression of fibrosis by histology at month 24 will serve as the basis for potential accelerated approval with clinical outcomes to support the potential for confirmatory or full approval— SAN FRANCISCO, May 14, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and
- GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, May 10, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 48,150 shares of the Company’s common stock to four new employ
- GuruFocus.com
89bio Inc (ETNB) Reports Increased Losses in Q1 2024 Despite Advancements in Clinical Trials
Financial and Operational Highlights from the Latest Earnings Report
